Pharma patent agreements ‘contrary’ to EU competition law
The Court of Justice for the EU (CJEU) has ruled that a settlement agreement between a pharma patent holder and a generic
manufacturer not to enter a specific market in return for monetary payments, is contrary to EU competition law.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.